Stimulant use in suicides: A systematic review

Mantinieks, Dylan; Schumann, Jennifer; Drummer, Olaf H.; Woodford, Noel; Gerostamoulos, Dimitri

doi:10.1016/j.forsciint.2022.111391

Cited by 7 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among treatments indicated for weight loss in adults with obesity, GLP‐1RAs would not be alone in raising concerns of suicidality. Phenteramine, found in the weight loss combination phenteramine/topiramate, is a stimulant, a class of agents, which are over‐represented in suicide completers relative to the general population 56 . Anti‐epileptic medications, such as topiramate, have controversially been associated with suicidal ideation, and anti‐epileptic medications in the United States carry a black box warning for suicidality 57 .…”

Section: Potential Explanations For An Association Between Glp‐1ras A...mentioning

confidence: 99%

“…Phenteramine, found in the weight loss combination phenteramine/topiramate, is a stimulant, a class of agents, which are over-represented in suicide completers relative to the general population. 56 Anti-epileptic medications, such as topiramate, have controversially been associated with suicidal ideation, and anti-epileptic medications in the United States carry a black box warning for suicidality. 57 Bupropion, found in the weight loss combination bupropion/naltrexone, is a newgeneration serotonergic-noradrenergic antidepressant.…”

Section: Glp-1ras Are Active On the Cns And May Alter Moodmentioning

confidence: 99%

See 1 more Smart Citation

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?

Lau,

Gamble

2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Section: Potential Explanations For An Association Between Glp‐1ras A...mentioning

confidence: 99%

Section: Glp-1ras Are Active On the Cns And May Alter Moodmentioning

confidence: 99%

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?

Lau,

Gamble

2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Considerations for Determining Whether Drug Addiction Is a Disability

Hirsch,

Mandel,

Hegmann

et al. 2023

Guides Newsletter

View full text Add to dashboard Cite

There is an epidemic of drug overdose–related fatalities. Recent data indicate that the age-adjusted death rate from overdoses nearly quintupled over a 20-year period (2001-2021) to 32.4 per 100,000. More than 70% of these fatalities were caused by opioid overdose, especially the synthetic drug, fentanyl. Despite an increase in substance abuse and dependency treatment, mortality and morbidity associated with opioid, cocaine, psychostimulant, benzodiazepine, alcohol, and tobacco use disorders continue to rise. To better understand the factors contributing to this crisis, the multifaceted phenomenon of drug addiction is explored. The controversial chronic, relapsing “disease of the brain” model, which emphasizes the role of the neurotransmitter dopamine, the ventral tegmental area, and the nucleus accumbens, is critically considered. In addition, more expansive neurobiological models that include a host of other neurotransmitters, brain regions, and cognitive processes, as well as classical and operant conditioning and social learning theory to help better understand compulsive drug taking, tolerance, risk-taking, and relapse, were examined. For this, the roles of genetics and epigenetics vs individual agency in drug addiction were considered. The economic and occupational consequences borne both individually and societally are enormous. Ultimately, whether the presence of drug addiction satisfies the criteria for a disability remains a conundrum, especially from the perspectives of financial support (eg, Social Security, private insurance companies) vs regulation (eg, licensing agencies).

show abstract

Methylamphetamine toxicity and its involvement in death: A retrospective observational study of deaths reported to the Victorian Coroner, Australia

Mantinieks,

Archer,

Schumann

et al. 2023

Forensic Sci Med Pathol

View full text Add to dashboard Cite

A retrospective observational study of Victorian deaths involving MA between 2010 and 2019 was conducted to determine the prevalence and contribution of methylamphetamine (MA) toxicity to death in the absence of other factors. Demographics, autopsy findings, toxicology, and the cause of death were reviewed. Coronial cases were categorized into five groups: deaths due to MA toxicity in the absence of other factors (Group A1); deaths due to MA toxicity in the setting of other potentially contributing factors (Group A2); deaths due to MA toxicity in the setting of significant natural disease (Group B); deaths primarily due to multiple-drug toxicity (Group C); and deaths primarily due to natural causes (Group D). There were 506 deaths involving MA categorized into Group A1 (n = 1, 0.6%), Group A2 (n = 8, 1.6%), Group B (n = 28, 5.5%), Group C (n = 229, 45%), and Group D (n = 240, 47%). Significant natural disease was prevalent among deaths involving MA and mainly concerned forms of cardiovascular disease (n = 277, 55%). The MA concentration in the one death included in Group A1 was 2.1 mg/L. The median MA concentrations of Group A2 (1.6 mg/L) and Group B (0.5 mg/L) were significantly higher than Group C (0.2 mg/L) and Group D (0.2 mg/L). Additionally, many other toxicologically significant drugs were detected and mostly comprised of central nervous system depressants. Deaths due to MA toxicity in the absence of other factors were rare despite the greater availability of crystal MA in the Australian community. The study highlights the interpretative challenges of MA blood concentrations and the continuing harms of this drug in Australia.

show abstract

Stimulant use in suicides: A systematic review

Cited by 7 publications

References 51 publications

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?

Considerations for Determining Whether Drug Addiction Is a Disability

Methylamphetamine toxicity and its involvement in death: A retrospective observational study of deaths reported to the Victorian Coroner, Australia

Contact Info

Product

Resources

About